Bioequivalence study of three ascorbic acid tablet formulations in healthy male volunteers

dc.creatorMolina, PLG
dc.creatorRibeiro, W
dc.creatorMoraes, LA
dc.creatorPoli, A
dc.creatorAbib, E
dc.creatorMoreno, RA
dc.creatorLeahey, W
dc.creatorMoreno, H
dc.creatorMuscara, MN
dc.creatorde Nucci, G
dc.date1998
dc.date2014-07-30T13:52:06Z
dc.date2015-11-26T17:12:02Z
dc.date2014-07-30T13:52:06Z
dc.date2015-11-26T17:12:02Z
dc.date.accessioned2018-03-29T00:00:29Z
dc.date.available2018-03-29T00:00:29Z
dc.identifierClinical Research And Regulatory Affairs. Marcel Dekker Inc, v. 15, n. 2, n. 115, n. 130, 1998.
dc.identifier1060-1333
dc.identifierWOS:000074386500003
dc.identifier10.3109/10601339809019641
dc.identifierhttp://www.repositorio.unicamp.br/jspui/handle/REPOSIP/55570
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/55570
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1281239
dc.descriptionThis study compares the bioequivalence of three ascorbic acid formulations (test: Celong 500 mg prolonged release tablets from Whitehall; standard: Cewin 500 mg prolonged release tablets from Winthrop and Redoxon oral effervescent 1000 mg tablets from Roche) in seventeen healthy male volunteers. A single oral dose of 1000 mg of the appropriate formulation was administered according to a randomized cross-over way with a two week washout interval between periods. Plasma samples for HPLC determination of ascorbic acid were obtained before and at set intervals up to 48h after the administration of each formulation. From the plasma concentration vs. time curves obtained for each formulation, the following parameters were obtained: areas under the curves (AUC) from 0 to 12h and from 0 to 48h, maximum achieved concentration (C-max) and the time at which it occurred (T-max). Parametric and non-parametric analysis of individual AUC and C-max ratios and T-max differences among formulations showed no statistical significance, despite their different patterns of drug release. Based on the above results and in accordance with the European Union and the US Food and Drug Administration, Celong was found to be bioequivalent to both Cewin and Redoxon, and also Cewin was bioequivalent to Redoxon with regard to both the extent and rate of absorption.
dc.description15
dc.description2
dc.description115
dc.description130
dc.languageen
dc.publisherMarcel Dekker Inc
dc.publisherNew York
dc.publisherEUA
dc.relationClinical Research And Regulatory Affairs
dc.relationClin. Res. Regul. Affairs
dc.rightsfechado
dc.sourceWeb of Science
dc.subjectPerformance Liquid-chromatography
dc.subjectVitamin-c
dc.subjectElectrochemical Detection
dc.subjectDehydroascorbic Acid
dc.subjectIntestinal-absorption
dc.subjectHuman Ileum
dc.subjectGuinea-pig
dc.subjectDerivatization
dc.subjectPlasma
dc.titleBioequivalence study of three ascorbic acid tablet formulations in healthy male volunteers
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución